• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

    6/11/25 8:00:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email

    RINCON, Puerto Rico, June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time.

    "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input.

    More than one year has already passed since Quanterix held its last Annual Meeting on June 3, 2024, yet the 2025 Annual Meeting remains unscheduled. We believe the Board of Directors (the "Board") is using delay tactics to further disenfranchise shareholders by failing to hold an annual meeting on time.

    We believe that by delaying the 2025 Annual Meeting, the Board is actively avoiding shareholder accountability. This delay enables the Board to finalize controversial strategic actions, such as the Akoya merger, without facing direct shareholder feedback. We believe that the Board is also trying to delay the Annual Meeting until after closing the Akoya merger to dilute existing Quanterix shareholders' voting rights with newly issued shares to Akoya that are more likely to support the existing Board versus Kent Lake's slate of highly qualified director candidates.

    These tactics are unacceptable, and we call on the Board to immediately schedule and promptly hold the 2025 Annual Meeting. Shareholders should view any further delays in holding the 2025 Annual Meeting as a deliberate effort by the Board to disenfranchise existing shareholders of their voting rights.

    Further, if the Board would like to demonstrate it supports shareholder rights and accountability, we urge them to include a proposal to declassify the Board on the agenda for this upcoming meeting. Quanterix shareholders have suffered abysmal returns since the 2017 IPO under the current entrenched board, and a declassified board would be a major step towards restoring faith in Quanterix amongst the investment community."

    About Kent Lake

    Kent Lake Partners LP is an investment fund founded by Ben Natter in 2019 with a focus on small and mid-capitalization public equities, particularly in the healthcare space. Mr. Natter has over a decade of successful public healthcare equity investing experience.

    Certain Information Concerning the Participants

    Kent Lake Partners LP ("Kent Lake Partners"), together with the other Participants (as defined below), intends to file a preliminary proxy statement and an accompanying GOLD universal proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of Quanterix Corporation, a Delaware corporation (the "Company").

    KENT LAKE PARTNERS STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation are currently anticipated to be Kent Lake Partners, Kent Lake PR LLC ("Kent Lake PR") and Benjamin Natter (collectively, the "Kent Lake Parties"); and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the "Kent Lake Nominees" and collectively with the Kent Lake Parties, the "Participants").

    As of the date hereof, Kent Lake Partners directly beneficially owned 2,688,472 shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock"). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 2,688,472 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 2,688,472 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

    Cision View original content:https://www.prnewswire.com/news-releases/kent-lake-condemns-quanterixs-failure-to-schedule-its-2025-annual-meeting-as-a-tactic-to-silence-shareholders-302478206.html

    SOURCE Kent Lake PR LLC

    Get the next $QTRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    3/2/2022$85.00 → $60.00Overweight
    JP Morgan
    More analyst ratings

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

      RINCON, Puerto Rico, June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input. More than one year has already passed since Quanterix held its last Annual Meeting on June 3, 2024, yet the 2025 Annual Meeting remains unscheduled. We believe the Board

      6/11/25 8:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Present at Goldman Sachs Global Healthcare Conference

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at www.quanterix.com. A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit www.qu

      6/6/25 9:41:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Donnelly William P bought $506,348 worth of shares (93,113 units at $5.44), increasing direct ownership by 203% to 139,094 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:10:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/10/25 4:08:44 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Walt David R bought $1,133,796 worth of shares (210,000 units at $5.40), increasing direct ownership by 14% to 1,706,933 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:44:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Donnelly William P bought $506,348 worth of shares (93,113 units at $5.44), increasing direct ownership by 203% to 139,094 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      6/9/25 5:10:15 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Quanterix Corporation

      SC 13G - Quanterix Corp (0001503274) (Subject)

      6/27/24 2:46:59 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      2/14/24 4:57:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

      Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. ("EMISSION"). Quanterix expects the transaction will close in January 2025. "As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components," said Masoud Toloue, Chief Executive Officer of Quanterix. "EMISSION's proprietary bead technology has already been validated on our upcoming new Simoa platform and will en

      12/17/24 6:59:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis

      10/2/24 4:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Quanterix Corporation

      EFFECT - Quanterix Corp (0001503274) (Filer)

      6/13/25 12:15:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form POS AM filed by Quanterix Corporation

      POS AM - Quanterix Corp (0001503274) (Filer)

      6/3/25 9:24:17 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Quanterix Corporation

      SD - Quanterix Corp (0001503274) (Filer)

      6/2/25 4:50:04 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Financials

    Live finance-specific insights

    See more
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the Fourth Quarter of 2024

      Delivers seventh consecutive quarter of double-digit revenue growth Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. "During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and

      3/17/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Quanterix with a new price target

      Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

      2/1/24 6:32:54 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

      9/25/23 9:03:48 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix upgraded by SVB Securities with a new price target

      SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00

      8/8/23 6:29:03 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials